A moderate value in a man may signal a more advanced process
A protein fragment in the blood, long trusted as a neutral signal of neuronal damage, may speak a different language depending on the sex of the patient carrying it. A new synthesis of research finds that men with Alzheimer's disease show steeper cognitive and structural brain decline per unit rise in plasma neurofilament light chain than women with identical values, suggesting the same number can mean different things in different bodies. The finding arrives at a moment when medicine is beginning to reckon with the cost of universal thresholds — the quiet assumption that biology, in its most intimate details, does not vary by sex. What follows now is the harder work: building the reference data, the mechanistic understanding, and perhaps the differentiated treatments that a more honest reading of the evidence demands.
- A blood marker widely used to track Alzheimer's progression may be systematically underestimating disease severity in male patients, raising the stakes for clinical decisions made on its basis.
- Men show steeper losses in memory, brain volume, and metabolic activity for each incremental rise in NfL — a pattern specific enough to rule out simple differences in how the body processes the protein.
- The field's current practice of applying a single NfL threshold to all patients is now being called indefensible, as identical numbers may represent meaningfully different stages of neurodegeneration depending on sex.
- Competing biological explanations — from sex-differentiated microglial inflammation to estrogen's neuroprotective role to the structural reserve of larger male brains — remain plausible but unproven, leaving the mechanism an open question.
- Progress is further slowed by small and conflicting studies, expensive measurement platforms, and a lack of standardization across laboratories, with the burden falling hardest on under-resourced clinical settings.
- Researchers are calling for large, sex-stratified, lifespan-spanning reference datasets and mechanistic trials that could eventually determine whether men and women should receive different treatment thresholds — or different treatments altogether.
A blood test returns a number, and medicine has long assumed that number means the same thing in every patient. A new review, assembled by researchers at Fudan University and Wuhan University and published in Brain Medicine, challenges that assumption in a pointed way: the same level of plasma neurofilament light chain — a protein released when neurons begin to break down — may signal a more advanced disease process in men with Alzheimer's than in women with identical readings.
NfL has become one of the field's most valued tools precisely because it is accessible. Unlike PET scans, which are expensive and scarce, or spinal taps, which are uncomfortable and unrepeatable, a blood draw can be done again and again. The marker rises years before symptoms appear — in some high-risk families, up to fifteen years before the first memory lapse — and tracks the pace of neuronal loss alongside established measures of amyloid and tau pathology.
What the review finds, across multiple cohorts, is that men experience steeper declines in cognition, hippocampal volume, and brain metabolism for each unit rise in NfL. The pattern holds specifically for NfL; a related marker called p-tau181 ran in the opposite direction, and another, GFAP, showed no sex difference at all. That specificity points toward something real about how the injured male brain responds to neurodegeneration, rather than a simple artifact of how the protein circulates or clears.
The authors are careful about causation. Several mechanisms are plausible — sex differences in microglial inflammation, estrogen's proposed neuroprotective effects, or the possibility that larger male brains require more absolute damage to produce the same blood concentration — but none are proven in human studies. The evidence base remains small, findings conflict, and laboratory standardization is inconsistent, limiting comparability across clinical settings.
What the field needs, the review argues, is sex-stratified reference data drawn from diverse populations across the adult lifespan, replacing single thresholds with trajectories that account for both sex and age. Whether treatments themselves should differ by sex remains an equally open and consequential question — one that the work ahead has yet to answer.
A blood test tells you a number, but a new synthesis of research suggests clinicians may have been misreading what that number means—and the misreading breaks along sex lines. The marker in question is plasma neurofilament light chain, or NfL, a protein fragment released when neurons begin to fray. It is not specific to Alzheimer's disease; it rises in many neurological disorders. But once amyloid or tau pathology has anchored a diagnosis, NfL becomes something older tools cannot easily provide: a minimally invasive, repeatable window into how fast the brain is dying. You can draw blood again and again. You cannot repeat a spinal tap without discomfort, and positron emission tomography scans are expensive and scarce.
The review, published in Brain Medicine and assembled by researchers at Fudan University and Wuhan University, pulls together a decade of scattered findings to argue that the same NfL level may carry different weight depending on whether the patient is male or female. The pattern they identify is striking. Across multiple cohorts, men showed steeper decline in cognition, brain structure, and brain function for each unit rise in plasma NfL. The effect was specific to NfL itself. A related marker called p-tau181 ran in the opposite direction. Another, GFAP, showed no such split. This specificity suggests the difference is not simply a matter of how the body clears the protein differently in each sex, but rather points to a distinct vulnerability in the injured male brain.
NfL has become valuable precisely because it moves. It does not merely announce that damage exists; it measures how quickly the damage is unfolding. The review notes that in families carrying autosomal dominant Alzheimer's mutations, NfL levels begin climbing measurably years before symptoms appear—in some studies, up to fifteen years before the first lapse of memory. Higher concentrations align with poorer cognitive test scores, with shrinkage of the hippocampus on MRI, and with dimmed brain metabolism on imaging. Within the field's established framework for understanding Alzheimer's pathology, NfL has become the marker of neurodegeneration itself, completing the picture alongside amyloid and tau.
The clinical implication is direct and unsettling. A moderate NfL value in a man may signal a more advanced disease process than the identical value in a woman. Treating the two as equivalent risks underestimating how far the disease has progressed in male patients. This challenges the assumption that a single threshold can serve all patients equally. The authors argue that one-size-fits-all interpretation of this marker is no longer defensible.
On the question of why this happens, the review is careful to distinguish hypothesis from fact. Several mechanisms remain plausible but unproven. Male and female immune cells in the brain, called microglia, appear to differ in their inflammatory wiring; a fiercer neuroinflammatory environment in men could mean that a given amount of NfL release travels alongside greater collateral damage. Estrogen has long been proposed as neuroprotective, while testosterone may shield the male brain until its age-related decline. Men carry, on average, larger brains and more white matter, so perhaps more absolute injury is required to raise the same blood concentration—an idea borrowed from the older concept of brain reserve. The authors weigh these possibilities and note that peripheral factors like blood-brain barrier permeability or kidney clearance would shift raw concentration, not the strength of the marker's link to disease severity.
Yet the field remains constrained by what it does not know. The body of work directly examining sex and plasma NfL is small, and findings conflict. The mechanistic proposals rest largely on animal models and remain unproven in people. Practical barriers compound the problem. The ultrasensitive platforms that measure NfL are expensive, and the lack of standardization across laboratories makes results difficult to compare—a problem felt most sharply in community clinics and resource-limited settings. What the field needs next, the authors argue, is large, sex-stratified reference data spanning the adult lifespan and drawn from diverse populations. Single thresholds should give way to trajectories that account for both sex and age. An equally open question remains: will treatments themselves slow neuronal injury differently in men and women? That answer, too, awaits the work ahead.
Notable Quotes
A moderate value in a man may signal a more advanced process than the identical value in a woman. Treating the two as equivalent risks underestimating how far the disease has traveled in male patients.— Dr. Yingfeng Xia, Wuhan University
We see a real and consistent signal, and the biology beneath it still has to be earned, experiment by experiment.— Dr. Guoqiang Fei, Fudan University
The Hearth Conversation Another angle on the story
So this protein, NfL—it's just a messenger, right? It doesn't tell you what's wrong, only that something is.
Exactly. It's smoke from a fire, but it doesn't name the fire. It rises in many disorders. What makes it valuable is that once you know the diagnosis—once you know it's Alzheimer's—NfL tells you the speed of the damage. That's what clinicians have been desperate for.
And the sex difference—is that saying men get sicker faster?
Not necessarily faster. It's saying that at the same NfL level, men show steeper cognitive decline and more brain shrinkage. The same number means something different in a man's body than in a woman's.
That's unsettling. How do we know it's not just that men and women clear the protein differently?
Because the effect is specific to NfL. Other markers like p-tau181 don't show this split. If it were just clearance, you'd expect all markers to shift the same way. This points to something about how the male brain responds to injury itself.
Do they know what that something is?
Not yet. They have working hypotheses—differences in immune cell behavior, hormonal protection, even brain size. But those are threads, not conclusions. The honest answer is they see a real signal and the biology beneath it still has to be earned.
What happens clinically? Does this change how doctors treat men versus women?
That's the question the field is asking now. Right now, it means a doctor reading an NfL value in a man should interpret it as more advanced disease than the same value in a woman. But whether treatments should differ—that's still open.